This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Vectra ®DA Identified Patients in SWEFOT Clinical Study at Higher Risk of Joint Damage
SALT LAKE CITY, June 10, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that Vectra
® DA data will be featured in eight posters at the 2014 European League Against Rheumatism (EULAR) Annual Meeting, June 11–14, 2014, in Paris, France. Vectra DA is a quantitative, objective multi-biomarker test to measure disease activity in patients with rheumatoid arthritis (RA). The Vectra DA test offers insight into the biological processes that drive disease activity to help rheumatologists manage RA and improve patient care.
At EULAR, data will be presented by researchers from the Swedish Farmacotherapy (SWEFOT) clinical trial that demonstrate the clinical utility of Vectra DA in assessing the risk of future joint damage at multiple points in time. Additionally, SWEFOT data indicate that changes in Vectra DA scores were associated with favorable response to both non-biologic and biologic therapies. Further, the data demonstrate that Vectra DA may have the potential to serve as an inclusion criterion for assessing patients who are candidates for clinical trials in rheumatoid arthritis.
"The breadth of data presented at EULAR is representative of the clinical utility of Vectra DA in the overall management of RA," said Oscar Segurado, chief medical officer at Crescendo Bioscience. "Vectra DA provides physicians with important, actionable insight to better assess risk of radiographic progression as well as manage therapy decisions in their patients with a precise and standardized tool. The EULAR data also point out the opportunity to identify more patients that may be eligible to participate in clinical trials."